Johnson & Johnson enters US robotic surgery market with FDA-approved OTTAVA system

Johnson & Johnson has officially entered the United States soft-tissue robotic surgery market following the receipt of FDA De Novo authorization for its OTTAVA robotic surgical system. The approval allows the medical technology conglomerate to commence a selective commercial launch in the US, focusing initially on early customer success, surgeon training, and workflow integration. This milestone represents a strategic expansion for the company’s MedTech division, positioning it to compete directly with established players in a sector previously dominated by a single major provider.

The OTTAVA system distinguishes itself through a table-integrated architecture, where robotic arms are incorporated directly into the operating table. Johnson & Johnson states this design occupies 30% to 50% less space than traditional boom- or cart-mounted systems, a feature the company believes could make robotic surgery accessible to operating rooms with limited capacity. The initial FDA authorization covers multiple upper-abdominal general surgery procedures, including gastric bypass, gastrectomy, cholecystectomy, gastric sleeve surgery, appendectomy, and hiatal hernia repair.

The launch strategy is deliberately measured, reflecting the complex requirements of robotic surgery adoption beyond mere regulatory clearance. Hospitals require robust training for surgeons and staff, seamless integration into existing workflows, and sufficient procedure volumes to justify the capital investment. By starting with select customers, Johnson & Johnson aims to collect real-world feedback and refine the platform before pursuing broader commercial expansion. The company also notes an ongoing US clinical trial for OTTAVA in inguinal hernia procedures, which could further broaden the system’s addressable market.

This development places Johnson & Johnson in direct competition with Intuitive Surgical, the current market leader. As of the second quarter of 2026, Intuitive Surgical held an installed base of 11,710 da Vinci systems, a figure that grew by 12% from the previous year. The company’s business model extends beyond hardware sales, generating significant recurring revenue from instruments, accessories, services, and leasing arrangements. In the second quarter of 2026, Intuitive Surgical reported revenue of $2.89 billion, an 18% increase, driven by an 18% rise in instruments and accessories revenue and a 16% growth in procedure volume.

For investors, the key metrics to monitor will be the pace of OTTAVA placements and the extent to which the system’s smaller footprint influences hospital purchasing decisions. While Johnson & Johnson brings a broader surgical portfolio that could aid commercial access, the degree to which these relationships translate into robotic-system placements remains to be seen. The authorization marks the beginning of a commercial challenge, but Intuitive Surgical’s entrenched ecosystem and continued double-digit growth suggest its leadership position remains secure in the near term.